Stryker Co. (NYSE:SYK) Position Increased by Cetera Advisors LLC

Cetera Advisors LLC raised its holdings in shares of Stryker Co. (NYSE:SYK) by 3.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,740 shares of the medical technology company’s stock after purchasing an additional 197 shares during the period. Cetera Advisors LLC’s holdings in Stryker were worth $1,243,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Cetera Advisor Networks LLC grew its position in shares of Stryker by 5.1% during the third quarter. Cetera Advisor Networks LLC now owns 4,675 shares of the medical technology company’s stock worth $1,013,000 after acquiring an additional 228 shares during the last quarter. Trillium Asset Management LLC grew its position in shares of Stryker by 20.0% during the third quarter. Trillium Asset Management LLC now owns 22,090 shares of the medical technology company’s stock worth $4,778,000 after acquiring an additional 3,688 shares during the last quarter. Goelzer Investment Management Inc. grew its position in shares of Stryker by 2.2% during the third quarter. Goelzer Investment Management Inc. now owns 9,312 shares of the medical technology company’s stock worth $2,014,000 after acquiring an additional 203 shares during the last quarter. Rational Advisors LLC grew its position in shares of Stryker by 4,136.4% during the third quarter. Rational Advisors LLC now owns 10,718 shares of the medical technology company’s stock worth $2,318,000 after acquiring an additional 10,465 shares during the last quarter. Finally, Everett Harris & Co. CA grew its position in shares of Stryker by 1.0% during the third quarter. Everett Harris & Co. CA now owns 5,759 shares of the medical technology company’s stock worth $1,246,000 after acquiring an additional 58 shares during the last quarter. Hedge funds and other institutional investors own 73.13% of the company’s stock.

In other Stryker news, CFO Glenn S. Boehnlein sold 2,700 shares of the company’s stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $215.85, for a total value of $582,795.00. Following the completion of the sale, the chief financial officer now directly owns 17,933 shares of the company’s stock, valued at approximately $3,870,838.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP M Kathryn Fink sold 28,690 shares of the company’s stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $220.97, for a total transaction of $6,339,629.30. The disclosure for this sale can be found here. Insiders sold a total of 62,508 shares of company stock valued at $13,643,782 over the last three months. 7.20% of the stock is owned by corporate insiders.

Shares of SYK opened at $206.25 on Friday. The firm has a 50-day moving average price of $211.01 and a 200 day moving average price of $206.13. The firm has a market capitalization of $74.89 billion, a PE ratio of 28.21, a P/E/G ratio of 2.45 and a beta of 0.80. The company has a quick ratio of 1.35, a current ratio of 2.18 and a debt-to-equity ratio of 0.64. Stryker Co. has a 52-week low of $144.75 and a 52-week high of $223.45.

Stryker (NYSE:SYK) last announced its earnings results on Tuesday, October 29th. The medical technology company reported $1.91 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.90 by $0.01. The firm had revenue of $3.59 billion during the quarter, compared to analyst estimates of $3.58 billion. Stryker had a net margin of 23.55% and a return on equity of 25.33%. Stryker’s revenue was up 10.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.69 EPS. On average, equities analysts expect that Stryker Co. will post 8.23 EPS for the current year.

Several equities analysts have recently commented on the stock. Canaccord Genuity upped their price target on shares of Stryker from $233.00 to $240.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Robert W. Baird upped their price target on shares of Stryker from $239.00 to $242.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Piper Jaffray Companies restated a “buy” rating on shares of Stryker in a research report on Wednesday, September 4th. Royal Bank of Canada set a $220.00 price target on shares of Stryker and gave the stock a “buy” rating in a research report on Friday, July 26th. Finally, Cantor Fitzgerald upped their price target on shares of Stryker from $190.00 to $230.00 and gave the stock a “neutral” rating in a research report on Friday, July 26th. Six research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $220.17.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Recommended Story: What is the LIBOR?

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.